Abstract
The standard-of-care (SOC) first-line therapy for ovarian cancer (OC) patients is plagued with high relapse rates. Several studies indicated the immune system’s prominent role changing the disease course in OC patients. Chemo-immunotherapy regimens, currently being explored, include oregovomab, which is a monoclonal antibody specific for the OC associated antigen carbohydrate/cancer antigen 125 (CA125) that yielded promising results when administered together with SOC in a previous study. The QPT-ORE-002 multi-site phase II randomized study demonstrated that in patients with advanced OC, oregovomab combined with first-line SOC improved overall and progression-free survival, compared to SOC alone. The study included an Italian cohort in which we demonstrated that adding oregovomab to SOC resulted in increased patient numbers with amplified CA125-specific CD8+T lymphocytes/ml peripheral blood counts, which might explain the improved therapeutic effect of SOC + oregovomab over SOC alone. Predictive for oregovomab efficacy was a less suppressive immune environment at baseline as indicated by low numbers of circulating myeloid-derived suppressor cells, subset type 4, and a low neutrophil-and-monocyte to lymphocyte ratio.
Lingua originale | English |
---|---|
pagine (da-a) | 383-397 |
Numero di pagine | 15 |
Rivista | Cancer Immunology, Immunotherapy |
Volume | 69 |
DOI | |
Stato di pubblicazione | Pubblicato - 2020 |
Keywords
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin
- Female
- Humans
- Immune response
- Immunotherapy
- Middle Aged
- Oregovomab
- Ovarian Neoplasms
- Ovarian cancer
- Paclitaxel
- Personalized medicine
- Precision Medicine
- Predictive biomarkers